BMJ:皮肤克罗恩病案例报道

2015-12-22 Mechront译 MedSci原创

25岁女性,双侧乳房和双侧腹股沟皮肤溃烂伴疼痛。1个月前皮损周围部位出现过蜂窝组织炎,最初静脉注射抗生素治疗,但蜂窝组织炎反复发作。18岁时候因克罗恩病行了全结肠切除术。她还有严重的学习障碍和行为问题。(图片来自BMJ)规律服用美沙拉秦1500 mg/d,以及氯氮平。结肠切除术口服高剂量糖皮质激素使其出现明显瞬态精神病,此后未再使用过系统性皮质类固醇。她很肥胖,乳房、腹股沟等肉肉折叠区域有深深的皮

25岁女性,双侧乳房和双侧腹股沟皮肤溃烂伴疼痛。1个月前皮损周围部位出现过蜂窝组织炎,最初静脉注射抗生素治疗,但蜂窝组织炎反复发作。18岁时候因克罗恩病行了全结肠切除术。她还有严重的学习障碍和行为问题。


(图片来自BMJ)

规律服用美沙拉秦1500 mg/d,以及氯氮平。结肠切除术后口服高剂量糖皮质激素使其出现明显瞬态精神病,此后未再使用过系统性皮质类固醇。

她很肥胖,乳房、腹股沟等肉肉折叠区域有深深的皮损,就像刀割的一样。大阴唇也有溃疡。

细菌、念珠菌、HSV感染均阴性。皮肤活检示非特异性皮肤疤痕,更深层皮肤示非干酪样肉芽肿性炎。

问题:

1.该患者需要排除的鉴别诊断有哪些?
2.哪些检查可以确诊?
3.如何管理该疾病或患者?
4.还可以出现哪些皮肤表现?

答案:

1.线性腐蚀性HSV感染、皮肤的克罗恩病、细菌和真菌感染。

2.皮肤活检提示干酪样肉芽肿性炎,与胃肠道的克罗恩病相似。(患者为皮肤克罗恩病。)

3.需要包括皮肤和胃肠病学团队组成的多学科方法,局部和全身使用类固醇、甲硝唑、抗肿瘤坏死因子的药物对该疾病有一定作用。

4.皮肤的特异性表现如瘘管、裂缝或口腔溃疡;结节性红斑和脓皮病坏疽;皮肤疾病如白癜风、银屑病和化脓性汗腺炎等。

原始出处:

Adam Daunton,J M R Goulding.A cutaneous presentation of a common condition.BMJ 2015;351:h6711

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1847816, encodeId=8a3e184e816b1, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Mar 23 06:57:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56468, encodeId=32945646834, content=值得关注的病例, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b601674185, createdName=小梁同志, createdTime=Tue Jan 12 20:53:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51363, encodeId=88465136321, content=支持病例讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 03 04:03:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51364, encodeId=5c54513641f, content=很有意思的病例, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 03 04:03:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49540, encodeId=a38549540c1, content=很好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 19:24:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
    2016-03-23 仁者大医
  2. [GetPortalCommentsPageByObjectIdResponse(id=1847816, encodeId=8a3e184e816b1, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Mar 23 06:57:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56468, encodeId=32945646834, content=值得关注的病例, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b601674185, createdName=小梁同志, createdTime=Tue Jan 12 20:53:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51363, encodeId=88465136321, content=支持病例讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 03 04:03:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51364, encodeId=5c54513641f, content=很有意思的病例, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 03 04:03:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49540, encodeId=a38549540c1, content=很好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 19:24:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
    2016-01-12 小梁同志

    值得关注的病例

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1847816, encodeId=8a3e184e816b1, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Mar 23 06:57:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56468, encodeId=32945646834, content=值得关注的病例, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b601674185, createdName=小梁同志, createdTime=Tue Jan 12 20:53:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51363, encodeId=88465136321, content=支持病例讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 03 04:03:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51364, encodeId=5c54513641f, content=很有意思的病例, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 03 04:03:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49540, encodeId=a38549540c1, content=很好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 19:24:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
    2016-01-03 lu2996

    支持病例讨论

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1847816, encodeId=8a3e184e816b1, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Mar 23 06:57:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56468, encodeId=32945646834, content=值得关注的病例, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b601674185, createdName=小梁同志, createdTime=Tue Jan 12 20:53:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51363, encodeId=88465136321, content=支持病例讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 03 04:03:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51364, encodeId=5c54513641f, content=很有意思的病例, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 03 04:03:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49540, encodeId=a38549540c1, content=很好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 19:24:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
    2016-01-03 lu2996

    很有意思的病例

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1847816, encodeId=8a3e184e816b1, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Mar 23 06:57:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56468, encodeId=32945646834, content=值得关注的病例, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b601674185, createdName=小梁同志, createdTime=Tue Jan 12 20:53:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51363, encodeId=88465136321, content=支持病例讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 03 04:03:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51364, encodeId=5c54513641f, content=很有意思的病例, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 03 04:03:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49540, encodeId=a38549540c1, content=很好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 19:24:00 CST 2015, time=2015-12-27, status=1, ipAttribution=)]
    2015-12-27 忠诚向上

    很好学习

    0

相关资讯

新药Entyvio(vedolizumab)单抗能用于中至重度活动性溃疡性结肠炎和克罗恩病

武田(Tkeda)6月17日宣布,在美国推出单抗药物Entyvio(vedolizumab),该药于2014年5月获FDA和欧盟批准,用于中度至重度活动性溃疡性结肠炎(ulcerative colitis,UC)和克罗恩病(Crohn's disease,CD)成人患者的治疗。 Vedolizumab生物制品许可申请(BLA)和上市许可申请(MAA)的提交,是根据GEMINI项目的汇总数据,